{"gene":"SMARCB1","run_date":"2026-06-10T07:46:35","timeline":{"discoveries":[{"year":1995,"finding":"Drosophila SNR1 (ortholog of human SMARCB1/INI1) physically associates with the Brahma (BRM) protein and is a component of a large (>2×10^6 Da) SWI/SNF-like chromatin-remodeling complex in Drosophila, as demonstrated by co-immunoprecipitation from fly extracts. SNR1 and BRM genetically interact with trithorax (trx), supporting a cooperative role in maintaining homeotic gene transcription.","method":"Co-immunoprecipitation from Drosophila extracts; genetic interaction analysis; biochemical fractionation","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus genetic epistasis, replicated across multiple studies in the field","pmids":["7579694"],"is_preprint":false},{"year":1998,"finding":"The C-terminal SET domain of ALL-1 (human) and TRITHORAX (Drosophila) physically interact with INI1/hSNF5 (human) and SNR1 (Drosophila), respectively. Interaction was demonstrated by yeast two-hybrid, in vitro binding assays, and co-immunoprecipitation from cultured cells and transgenic flies. SNR1 co-localizes with ~half of TRX binding sites on polytene chromosomes, suggesting SWI/SNF recruitment to ALL-1/TRX target loci via these physical contacts.","method":"Yeast two-hybrid screen; in vitro pulldown; co-immunoprecipitation from cells and transgenic flies; polytene chromosome immunostaining","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (Y2H + in vitro binding + Co-IP + localization), confirmed in two species","pmids":["9539705"],"is_preprint":false},{"year":2002,"finding":"Re-expression of INI1/hSNF5 in INI1-deficient rhabdoid tumor cells (MON) causes G0/G1 cell cycle arrest and flat cell formation. INI1 directly represses cyclin D1 transcription in an HDAC-dependent manner: chromatin immunoprecipitation showed INI1 is recruited to the cyclin D1 promoter, correlating with HDAC1 recruitment and histone deacetylation at that promoter. Ectopic cyclin D1 expression from a heterologous promoter rescued the INI1-mediated arrest.","method":"Retroviral re-expression; flow cytometry; ChIP; HDAC inhibitor experiments; rescue with ectopic cyclin D1; truncation analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct ChIP at cyclin D1 promoter, HDAC dependence, functional rescue, multiple orthogonal approaches in one study","pmids":["12138206"],"is_preprint":false},{"year":2002,"finding":"Re-expression of hSNF5/INI1/BAF47 in INI1-deficient rhabdoid tumor cell lines induces G1 arrest associated with strong induction of p16ink4a and hypophosphorylation (activation) of RB, establishing that hSNF5 signals upstream of RB to induce growth arrest. Co-expression of SV40 T/t antigen or HPV-16 E7 (which inactivates RB) abrogated hSNF5-induced arrest.","method":"Retroviral re-expression; flow cytometry; Western blot; rescue with SV40 T/t or HPV E7","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean re-expression in multiple cell lines with epistatic rescue experiments validating p16-RB pathway placement","pmids":["12149641"],"is_preprint":false},{"year":2002,"finding":"Re-introduction of INI1 into INI1-deficient cells causes G1 arrest and apoptosis (detected by cleaved PARP). Deletion analysis identified Repeats 1 and 2 of INI1 as required for growth suppression in a colony formation assay.","method":"Recombinant adenovirus-mediated overexpression; flow cytometry; BrdU incorporation; colony formation; PARP cleavage assay; deletion mutagenesis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — functional domain mapping by mutagenesis plus multiple cell-biological readouts in single study","pmids":["12082626"],"is_preprint":false},{"year":2003,"finding":"Drosophila SNR1 is an essential but tissue-selective subunit of the Brm (SWI/SNF) complex. A temperature-sensitive allele (snr1E1) with a single amino acid substitution in the conserved Repeat 2 region reduces Brm complex function. SNR1 can make direct contacts through its Repeat 2 region with the SET domain of Trithorax (TRX), and snr1E1 is partially defective for TRX association, establishing Repeat 2 as critical for protein–protein interaction and growth control.","method":"Genetic allele analysis; temperature-shift experiments; Co-IP; in vitro binding; polytene chromosome immunostaining","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic + biochemical + structural domain mapping with multiple orthogonal methods","pmids":["12482982"],"is_preprint":false},{"year":2003,"finding":"Drosophila SNR1 is required for a subset of Brm complex functions in vivo; SNR1-deficient imaginal tissues show altered gene expression patterns. Genome-wide localization shows SNR1 and BRM co-occupy many chromosomal loci but SNR1 is not required in all tissues dependent on BRM, indicating SNR1 acts as an optional subunit directing complex activity to specific loci.","method":"Genetic loss-of-function analysis; polytene chromosome immunostaining; in vivo somatic clone analysis","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic analysis plus localization in single organism, no direct biochemical reconstitution","pmids":["12645932"],"is_preprint":false},{"year":2004,"finding":"Re-induction of hSNF5/INI1 in rhabdoid tumor cells leads to reversible G1 arrest, down-regulation of DNA replication complex components, and dramatic reorganization of the actin cytoskeleton including disruption of actin stress fibers and focal adhesions. INI1 induction strongly decreases RhoA GTPase activity, suggesting that INI1 regulates actin organization through the Rho pathway.","method":"Tetracycline-inducible expression system; genome-wide microarray (22,000 genes); estrogen receptor fusion to identify direct targets; Rho activity assay; cell morphology imaging","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genome-wide target identification combined with functional Rho activity assay and direct-target fusion protein approach in one rigorous study","pmids":["15150092"],"is_preprint":false},{"year":2004,"finding":"In Drosophila, SNR1 mediates associations between the Brm chromatin-remodeling complex and CyclinE/CDK2 both in vitro and in vivo. Disruption of snr1 suppresses DmcycE phenotypes and loss of snr1 function reduces transcription of the G2-M regulator string/cdc25, implicating SNR1 in G1-S control and G2-M progression.","method":"In vitro binding assay; genetic epistasis (double mutant analysis); transcription assay","journal":"Genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro interaction plus genetic epistasis, Drosophila ortholog study","pmids":["15454538"],"is_preprint":false},{"year":2006,"finding":"Drosophila DYRK2 (dDYRK2) and Minibrain (MNB) interact with SNR1 (the SMARCB1 ortholog) as demonstrated by yeast two-hybrid and co-immunoprecipitation. Both kinases phosphorylate SNR1 at Thr102 in vitro and in vivo, representing the first identified phosphorylation of SNR1 or its homologs.","method":"Yeast two-hybrid; co-immunoprecipitation; in vitro kinase assay; in vivo phosphorylation","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphorylation confirmed both in vitro and in vivo in single study, Drosophila ortholog","pmids":["16671894"],"is_preprint":false},{"year":2006,"finding":"INI1 is specifically incorporated into HIV-1 virions. In INI1-deficient cells, HIV-1 particle production is severely reduced and infectivity is impaired; re-introduction of INI1 rescues particle production. Virions produced from INI1-null cells are defective for early and late reverse transcription products and for exogenous reverse transcriptase activity.","method":"HIV-1 infection of INI1-deficient rhabdoid cell lines; retroviral re-expression; RT assay; transduction assay","journal":"Retrovirology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional virology experiments in INI1-null lines with rescue; single lab","pmids":["16945155"],"is_preprint":false},{"year":2007,"finding":"Re-introduction of INI1 into rhabdoid cells activates interferon-stimulated genes at early time points, senescence markers at late time points, and represses mitotic genes including PLK1. RNAi knockdown of PLK1 in INI1-deficient rhabdoid cells causes mitotic arrest, aberrant nuclear division, and apoptosis, establishing PLK1 as a functionally relevant downstream effector of INI1.","method":"cDNA microarray; qRT-PCR; Western blot; IHC of primary tumors; RNAi knockdown; cell cycle/apoptosis assays; IFN treatment","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide target identification confirmed by RNAi functional epistasis and primary tumor validation; multiple methods","pmids":["17699849"],"is_preprint":false},{"year":2009,"finding":"INI1/hSNF5 forms multimeric structures; the Rpt1 and Rpt2 motifs constitute the minimal multimerization domain. Multimerization-defective mutants (identified by reverse yeast two-hybrid) are defective for nuclear retention, co-localization with HIV-1 integrase, and the transdominant inhibitory effect of the S6 fragment on HIV-1. INI1 also binds DNA in the minor groove; acceptor DNA binding may be required for stimulation of in vitro strand transfer by integrase.","method":"Protein purification; reverse yeast two-hybrid; deletion analysis; co-immunoprecipitation; in vitro strand transfer assay; nuclear localization imaging","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with mutagenesis, multiple biochemical assays in single rigorous study","pmids":["19398554"],"is_preprint":false},{"year":2012,"finding":"The SNR1/SNF5 subunit of the Drosophila Brm (SWI/SNF) complex controls RNA polymerase II elongation and pre-mRNA splicing at ecdysone-responsive genes. RNAi knockdown or conditional loss-of-function alleles show that a loss-of-function SNR1 subunit alters chromatin accessibility, RNA Pol II elongation, and splicing of specific hormone-regulated genes, restricting BRM-dependent nucleosome remodeling downstream of the promoter.","method":"RNAi knockdown in cultured Drosophila cells and transgenic flies; conditional mutant alleles; transcriptome profiling; chromatin accessibility assays","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with transcriptome readout and chromatin accessibility; Drosophila ortholog; single lab","pmids":["22467207"],"is_preprint":false},{"year":2013,"finding":"Restoration of Smarcb1 in Smarcb1-deficient mouse tumor cells abolishes xenograft growth and restores sensitivity to apoptosis without inducing growth arrest in vitro. Smarcb1 is required for transcriptional activation of Igfbp7 (a tumor suppressor); Smarcb1-deficient cells show persistent PI3K-mediated AKT activation, and AKT inhibition reduces proliferation and xenograft growth. Re-introduction of Igfbp7 alone inhibits tumor development.","method":"Retroviral re-expression; xenograft assay; AKT inhibitor treatment; gene expression profiling; Igfbp7 rescue experiment","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo xenograft rescue plus epistatic Igfbp7 re-expression and pharmacological pathway validation","pmids":["23851500"],"is_preprint":false},{"year":2013,"finding":"Restoration of SMARCB1 expression in epithelioid sarcoma cell line VAESBJ (which has a homozygous SMARCB1 deletion) significantly reduces cell proliferation, anchorage-independent growth, and cell migration, establishing a direct causal role for SMARCB1 loss in epithelioid sarcoma pathogenesis.","method":"SMARCB1 re-expression; colony formation; soft agar assay; wound-healing/migration assay","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean loss-of-function validated by re-expression with multiple cellular phenotype readouts; single lab","pmids":["23576573"],"is_preprint":false},{"year":2013,"finding":"The INI1-Rpt1 integrase-binding domain (IBD) forms a stable complex with HIV-1 integrase (IN), LEDGF/p75, and viral U5 DNA at a stoichiometry of 4 IN:2 LEDGF:2 INI1-IBD:2 DNA determined by mass spectrometry and fluorescence correlation spectroscopy. INI1-IBD inhibits the 3' processing reaction but not specific viral DNA binding. Cryo-EM locates INI1-IBD within the cellular DNA-binding site of the IN/LEDGF complex, constraining IN in a stable conformation that prevents non-specific interactions.","method":"In vitro reconstitution of multiprotein complex; mass spectrometry stoichiometry; fluorescence correlation spectroscopy; in vitro integration/3'-processing assay; cryo-electron microscopy","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — cryo-EM structure plus in vitro reconstitution and functional assays; multiple orthogonal methods in one study","pmids":["23593299"],"is_preprint":false},{"year":2014,"finding":"BAF47 (SMARCB1) loss destabilizes BAF complexes on chromatin without significantly altering complex assembly or integrity. Rescue of BAF47 in BAF47-deficient sarcoma cell lines increases genome-wide BAF complex occupancy (measured by ChIP-seq), leading to widespread enhancer activation and opposition of Polycomb-mediated repression at bivalent promoters. Two distinct mSWI/SNF assemblies (BAF and PBAF) differentially regulate enhancers and promoters, respectively.","method":"ChIP-seq for BAF complex occupancy; genome-wide enhancer and promoter analysis; re-expression of SMARCB1 in deficient cell lines","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genome-wide ChIP-seq with re-expression rescue, distinguishing two mSWI/SNF assemblies, single rigorous study with multiple orthogonal approaches","pmids":["28945250"],"is_preprint":false},{"year":2014,"finding":"BAF47/INI1 interacts with MyoD and is part of both the SWI/SNF remodeling complex and the N-CoR-1 repressor complex in proliferating myoblasts. Upon myogenic differentiation, BAF47 shifts toward the N-CoR-1 complex. BAF47 downregulation disrupts both the proliferation and differentiation gene programs, and only BAF47 (not BRG1) is essential for irreversible cell cycle exit during myoblast terminal differentiation.","method":"Co-immunoprecipitation; siRNA knockdown; ChIP; gene expression analysis during differentiation","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP complex identification plus functional knockdown with differentiation phenotype; single lab","pmids":["25271443"],"is_preprint":false},{"year":2016,"finding":"In Drosophila imaginal epithelial tissues, Snr1 (SMARCB1 ortholog) prevents neoplastic overgrowth by maintaining normal endosomal trafficking-mediated signaling. Unlike loss of any other SWI/SNF subunit, snr1 depletion alone induces neoplastic tumorigenic overgrowth. Snr1 is found in both nucleus and cytoplasm, and its loss aberrantly activates Notch, JNK, and JAK/STAT signaling pathways.","method":"Genetic loss-of-function (tissue-specific RNAi/clones); immunofluorescence localization; pathway reporter assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with pathway epistasis in Drosophila ortholog; single lab","pmids":["27923836"],"is_preprint":false},{"year":2017,"finding":"Crystal structure of the BAF155 SWIRM domain in complex with the BAF47 (SMARCB1) Repeat 1 (RPT1) domain was determined at high resolution. Extensive mutagenesis combined with isothermal titration calorimetry and NMR titrations confirmed the interface residues. The SWIRM domain of BAF155 is a modular domain responsible for interaction with BAF47, functionally distinct from DNA-binding SWIRM domains.","method":"X-ray crystallography; mutagenesis; isothermal titration calorimetry (ITC); NMR titration","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with mutagenesis and two independent biophysical validation methods (ITC + NMR)","pmids":["28438634"],"is_preprint":false},{"year":2017,"finding":"Timing of Smarcb1 and Nf2 inactivation determines tumor type: early Smarcb1 loss in neural crest initiates rhabdoid tumors in cranial nerves and meninges, whereas Smarcb1 loss at a later stage in the Schwann cell lineage combined with biallelic Nf2 inactivation generates schwannomas. This establishes a developmental stage-specific and cell-type-specific mechanism governing the two distinct SMARCB1-associated tumor syndromes.","method":"Tissue- and developmental stage-specific conditional knockout mice; histological and molecular profiling of resulting tumors","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic epistasis with stage- and lineage-specific conditional knockouts, generating two distinct tumor types; rigorous mouse model study","pmids":["28824165"],"is_preprint":false},{"year":2019,"finding":"In human embryonic stem cells (hESCs), SMARCB1 represses bivalent genes and antagonizes chromatin accessibility at super-enhancers. SMARCB1 is specifically required for neural induction but dispensable for mesodermal or endodermal differentiation, and is essential for super-enhancer silencing during neural differentiation conditions.","method":"SMARCB1 knockdown/loss-of-function in hESCs; ChIP-seq; ATAC-seq; directed differentiation assays","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide chromatin profiling (ChIP-seq, ATAC-seq) combined with directed differentiation lineage assays; multiple orthogonal approaches","pmids":["31033435"],"is_preprint":false},{"year":2020,"finding":"SMARCB1 loss in an inducible iPSC-based system interacts with neural differentiation state to cause resistance to terminal differentiation and defects in maintenance of normal cell state. The downstream effects of SMARCB1 loss are substantially different depending on the differentiation state of the cell.","method":"Inducible SMARCB1 loss-of-function in human iPSCs; directed neuronal differentiation; cerebral organoid differentiation; transcriptomic analysis","journal":"Genes & development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible system in iPSCs with differentiation state comparison; single lab","pmids":["32912900"],"is_preprint":false},{"year":2020,"finding":"SMARCB1 loss increases chromatin accessibility at the STAT3 locus in vitro, and SMARCB1 knockout cell lines show increased IL6/JAK/STAT3 signaling in orthotopic in vivo models. A pSTAT3 selective inhibitor (TTI-101) reduces tumor growth in SMARCB1 KO xenograft and patient-derived xenograft models, establishing the IL6/JAK/STAT3 axis as a SMARCB1-deficiency-driven vulnerability.","method":"SMARCB1 knockout; ATAC-seq; orthotopic xenograft models; pharmacological STAT3 inhibition; patient-derived xenograft","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — ATAC-seq mechanistic link plus in vivo validation in multiple models including PDX; multiple orthogonal approaches","pmids":["38355560"],"is_preprint":false},{"year":2020,"finding":"SMARCB1 directly binds the IL6 promoter in a steady state (ChIP), dissociates during immune activation, and acts as a direct transcriptional repressor of IL6. Loss- and gain-of-function studies confirm that SMARCB1 represses IL6 expression and loss of SMARCB1 reduces cell cycle progression via p21 upregulation.","method":"ChIP; loss- and gain-of-function (siRNA and overexpression); transcriptome analysis; flow cytometry","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP at IL6 promoter with functional rescue; single lab","pmids":["32492816"],"is_preprint":false},{"year":2020,"finding":"SMARCB1 upregulation in liver cancer contributes to SWI/SNF complex stability. SMARCB1 binds the enhancer of NUP210 (Nucleoporin 210) and regulates H3K27Ac enrichment there, changing NUP210 downstream gene expression (including cholesterol homeostasis and xenobiotic metabolism). NUP210 acts as a key scaffold for SMARCB1 and P300 on chromatin.","method":"ChIP-seq for SMARCB1 and H3K27Ac; loss- and gain-of-function in liver cancer cells; in vivo tumor models","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq identifying NUP210 as direct target with functional in vivo validation; single lab","pmids":["33239431"],"is_preprint":false},{"year":2021,"finding":"NMR structure of the INI1/SMARCB1 Rpt1 domain and modeling of its interaction with the HIV-1 integrase C-terminal domain (IN-CTD) reveal that INI1-Rpt1 interface residues overlap with those required for IN/RNA interaction. INI1-Rpt1 and TAR RNA compete for IN binding with similar IC50 values. Computational modeling suggests INI1-Rpt1 structurally mimics TAR RNA at the interface, explaining how INI1 influences HIV-1 late events via integrase.","method":"NMR structure determination; mutational analysis; competition binding assays (IC50); computational modeling","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure plus mutagenesis and competition binding assays; single study with multiple orthogonal methods","pmids":["33980829"],"is_preprint":false},{"year":2023,"finding":"SMARCB1 re-expression in renal medullary carcinoma (RMC) cells reverses a TFCP2L1→MYC transcriptional switch, repressing MYC and NFE2L2-associated oncogenic and ferroptosis-resistance programs, leading to ferroptotic cell death. SMARCB1 loss activates MYC and ferroptosis resistance programs in TAL (thick ascending limb) cell-derived RMC, linking SCT-associated hypoxia and iron environment to SMARCB1-mediated transformation.","method":"Single-cell RNA-seq of human RMC; SMARCB1 re-expression with transcriptomic analysis; ferroptosis assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — single-cell sequencing plus SMARCB1 re-expression with functional ferroptosis readout; multiple orthogonal methods","pmids":["37236926"],"is_preprint":false},{"year":2023,"finding":"SMARCB1 loss in malignant rhabdoid tumors leads to dramatic reshaping of the regulatory landscape including patient-specific looping of distal enhancer regions with the MYC oncogene promoter (demonstrated by chromosome conformation capture). SMARCB1 reconstitution reverses this epigenetic reprogramming. Intertumoral heterogeneity in MYC enhancer utilization is present in patient tissues.","method":"Multi-omics on patient-derived MRT organoids; SMARCB1 re-expression; chromosome conformation capture (Hi-C/4C); single-cell RNA-seq; single-cell ATAC-seq on patient tissues","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — chromosome conformation capture plus single-cell multi-omics in organoids and patient tissues; multiple orthogonal approaches","pmids":["38040699"],"is_preprint":false},{"year":2023,"finding":"Hypoxia induces SMARCB1 protein degradation in renal cells, protecting them from hypoxic stress. In a sickle cell trait mouse model, SMARCB1 wild-type renal tumors show lower SMARCB1 levels and more aggressive growth than controls; SMARCB1 reconstitution restores sensitivity to hypoxic stress in vitro and in vivo.","method":"In vitro hypoxia experiments; sickle cell trait mouse model; SMARCB1 re-expression; in vivo tumor growth assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo experiments with re-expression rescue; single lab","pmids":["37186844"],"is_preprint":false},{"year":2024,"finding":"DCAF5 (a CUL4-DDB1 substrate receptor) functions as a quality-control factor for SWI/SNF complexes: in the absence of SMARCB1, DCAF5 promotes degradation of incompletely assembled (SMARCB1-deficient) SWI/SNF complexes. DCAF5 depletion allows SMARCB1-deficient SWI/SNF complexes to re-accumulate, rebind target chromatin loci, and restore SWI/SNF-mediated gene expression to levels sufficient to reverse the cancer state, including in vivo. Thus, SMARCB1-mutant cancer results not from loss of SMARCB1 function per se, but from DCAF5-mediated degradation of residual SWI/SNF complexes.","method":"Genome-wide CRISPR screen (Cancer Dependency Map); DCAF5 depletion; ChIP-seq; gene expression analysis; in vivo xenograft assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genome-wide CRISPR screen plus mechanistic ChIP-seq and in vivo validation; multiple orthogonal methods in rigorous study","pmids":["38538798"],"is_preprint":false},{"year":2024,"finding":"In SMARCB1-deficient cancers, SMARCB1 loss leads to localization of H3K27ac and recruitment of CBP and p300 acetyltransferases at the KREMEN2 locus (rather than H3K27me3/EZH2 seen in SMARCB1-intact cells), resulting in KREMEN2 transcriptional upregulation. Simultaneous inhibition of CBP/p300 downregulates KREMEN2 and induces apoptosis via KREMEN1 monomerization and suppression of anti-apoptotic signaling, selectively in SMARCB1-deficient cells.","method":"Dual siRNA paralog synthetic lethal screen; ChIP-seq for H3K27me3, H3K27ac, EZH2, CBP, p300; CBP/p300 inhibitor treatment; xenograft models; KREMEN2 functional studies","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP-seq identifying mechanism plus synthetic lethality screen, in vivo validation, and functional mechanistic follow-up; multiple orthogonal methods","pmids":["38839769"],"is_preprint":false}],"current_model":"SMARCB1 (BAF47/INI1/SNF5) is a core, essential subunit of the SWI/SNF (BAF/PBAF) ATP-dependent chromatin remodeling complexes that stabilizes complex occupancy on chromatin; its loss triggers DCAF5-mediated proteasomal degradation of residual SWI/SNF complexes, collapsing enhancer activation and opposing Polycomb repression genome-wide. Mechanistically, SMARCB1 recruits HDAC activity to the cyclin D1 promoter to repress its transcription, activates p16ink4a to engage the RB pathway for G0/G1 arrest, activates interferon-stimulated genes and represses PLK1 to control mitotic fidelity, represses IL-6 transcription by direct promoter binding, regulates actin cytoskeleton organization through suppression of Rho GTPase activity, and in renal medullary carcinoma reverses a MYC/ferroptosis-resistance transcriptional program; its Rpt1 and Rpt2 domains mediate protein multimerization, interaction with BAF155 (via Rpt1/SWIRM interface defined by crystal structure), and interaction with HIV-1 integrase (mimicking TAR RNA), while developmental stage- and cell-type-specific loss of SMARCB1 determines whether rhabdoid tumors or schwannomas arise."},"narrative":{"mechanistic_narrative":"SMARCB1 (BAF47/INI1/SNF5) is an essential core subunit of the SWI/SNF (BAF/PBAF) ATP-dependent chromatin-remodeling complexes that functions as a tumor suppressor by stabilizing complex occupancy on chromatin and shaping enhancer and promoter activity genome-wide [PMID:7579694, PMID:28945250]. It does not govern complex assembly but is required for stable BAF complex residence on chromatin; its re-expression in deficient cells increases genome-wide BAF occupancy, drives widespread enhancer activation, and opposes Polycomb-mediated repression at bivalent promoters [PMID:28945250, PMID:31033435]. Within the complex, SMARCB1 multimerizes through its Rpt1 and Rpt2 motifs and docks onto BAF155 via a defined Rpt1–SWIRM interface resolved by crystallography [PMID:19398554, PMID:28438634]. SMARCB1 loss is the initiating lesion in rhabdoid tumors and related cancers; mechanistically, loss collapses normal regulation by enabling DCAF5-mediated proteasomal degradation of residual SMARCB1-deficient SWI/SNF complexes, such that DCAF5 removal restores complex accumulation, chromatin rebinding, and reversal of the cancer state [PMID:38538798]. Through these chromatin functions, SMARCB1 enforces growth arrest: it represses cyclin D1 in an HDAC-dependent manner, induces p16ink4a to activate the RB pathway and drive G0/G1 arrest, and represses mitotic genes including PLK1 while activating interferon-stimulated and senescence programs [PMID:12138206, PMID:12149641, PMID:17699849]. SMARCB1 also acts as a direct promoter-bound repressor of IL6 and antagonizes IL6/JAK/STAT3 signaling, suppresses RhoA activity to organize the actin cytoskeleton, and in renal medullary carcinoma reverses a MYC/ferroptosis-resistance transcriptional program [PMID:15150092, PMID:38355560, PMID:32492816, PMID:37236926]. Whether SMARCB1 loss produces rhabdoid tumors or schwannomas is dictated by the developmental stage and cell lineage in which inactivation occurs [PMID:28824165]. Independently of its chromatin role, SMARCB1/INI1 is incorporated into HIV-1 virions and binds HIV-1 integrase through an Rpt1-containing integrase-binding domain that structurally mimics TAR RNA, constraining integrase conformation and modulating viral late events [PMID:16945155, PMID:23593299, PMID:33980829].","teleology":[{"year":1995,"claim":"Established that SMARCB1's ortholog is a physical, integral component of a SWI/SNF-class chromatin-remodeling complex rather than a free-standing factor, defining its molecular context.","evidence":"Co-immunoprecipitation and biochemical fractionation of Drosophila SNR1 with BRM, plus genetic interaction with trithorax","pmids":["7579694"],"confidence":"High","gaps":["Did not define which human SWI/SNF subunits SMARCB1 contacts directly","Mechanism of recruitment to target loci unresolved"]},{"year":1998,"claim":"Identified a recruitment logic by showing the SET domain of ALL-1/Trithorax binds INI1/SNF5, linking SWI/SNF to homeotic/leukemia-relevant target loci.","evidence":"Yeast two-hybrid, in vitro pulldown, Co-IP, and polytene chromosome co-localization across human and Drosophila","pmids":["9539705"],"confidence":"High","gaps":["Functional consequence of the interaction at endogenous human loci untested","Did not address remodeling vs targeting roles"]},{"year":2002,"claim":"Defined SMARCB1 as a growth suppressor acting through the RB pathway, resolving how its loss promotes proliferation in rhabdoid tumors.","evidence":"Re-expression of INI1/hSNF5 in deficient cells with ChIP at cyclin D1, HDAC dependence, p16ink4a induction, RB hypophosphorylation, and epistatic rescue with cyclin D1, SV40 T/t, or HPV E7","pmids":["12138206","12149641","12082626"],"confidence":"High","gaps":["How chromatin remodeling activity connects mechanistically to cyclin D1/p16 regulation not fully resolved","Rpt1/Rpt2 requirement for growth suppression mapped but not structurally explained"]},{"year":2003,"claim":"Showed SMARCB1's ortholog is a tissue-selective, locus-directing subunit and mapped Repeat 2 as critical for protein interaction and growth control.","evidence":"Drosophila temperature-sensitive snr1E1 allele, Co-IP, in vitro binding, and genome-wide polytene localization showing partial BRM co-occupancy","pmids":["12482982","12645932"],"confidence":"High","gaps":["Tissue-selectivity mechanism in mammals untested","Did not define how Repeat 2 contacts the SET domain structurally"]},{"year":2004,"claim":"Linked SMARCB1 to cytoskeletal regulation, expanding its role beyond cell-cycle control.","evidence":"Tetracycline-inducible INI1 re-expression with genome-wide microarray, ER-fusion direct-target mapping, and RhoA activity assay","pmids":["15150092","15454538"],"confidence":"High","gaps":["Direct molecular link between SMARCB1 and RhoA pathway not established","Whether Rho regulation is chromatin-dependent unknown"]},{"year":2006,"claim":"Revealed a non-chromatin function: INI1 is packaged into HIV-1 virions and is required for productive particle production and infectivity.","evidence":"HIV-1 infection of INI1-null rhabdoid lines with re-expression rescue and reverse transcriptase assays; identification of SNR1 Thr102 phosphorylation by DYRK2/MNB","pmids":["16945155","16671894"],"confidence":"Medium","gaps":["Single-lab virology findings without independent replication","Functional role of Thr102 phosphorylation in mammals untested"]},{"year":2007,"claim":"Identified PLK1 repression and interferon/senescence activation as functionally relevant downstream programs of SMARCB1 controlling mitotic fidelity.","evidence":"cDNA microarray, qRT-PCR, primary tumor IHC, and RNAi knockdown of PLK1 showing mitotic arrest and apoptosis in INI1-deficient cells","pmids":["17699849"],"confidence":"High","gaps":["Direct promoter occupancy at PLK1 vs indirect effect not fully distinguished","Interferon gene activation mechanism unresolved"]},{"year":2009,"claim":"Defined the Rpt1/Rpt2 multimerization domain and connected multimerization to nuclear retention and HIV-1 integrase co-localization.","evidence":"Protein purification, reverse yeast two-hybrid, deletion analysis, Co-IP, in vitro strand transfer, and nuclear localization imaging","pmids":["19398554"],"confidence":"High","gaps":["In vivo relevance of multimerization to SWI/SNF function not addressed","DNA minor-groove binding role left preliminary"]},{"year":2013,"claim":"Demonstrated in vivo tumor-suppressor activity through Igfbp7/PI3K-AKT regulation and across multiple cancer types, extending SMARCB1 loss to causal pathogenesis.","evidence":"Retroviral re-expression with xenograft rescue, Igfbp7 re-expression, AKT inhibition in mouse tumor cells, and re-expression phenotyping in epithelioid sarcoma; HIV-1 integrase/LEDGF/DNA complex cryo-EM and stoichiometry","pmids":["23851500","23576573","23593299"],"confidence":"High","gaps":["How SMARCB1 selects Igfbp7 vs other targets unresolved","Whether Igfbp7/AKT axis operates in human rhabdoid tumors untested"]},{"year":2014,"claim":"Established the central chromatin mechanism: SMARCB1 stabilizes BAF complex occupancy genome-wide, activating enhancers and opposing Polycomb, without affecting complex assembly.","evidence":"ChIP-seq for BAF occupancy with SMARCB1 re-expression distinguishing BAF and PBAF enhancer/promoter roles; Co-IP placing BAF47 in SWI/SNF and N-CoR-1 complexes during myogenesis","pmids":["28945250","25271443"],"confidence":"High","gaps":["Molecular basis for chromatin stabilization vs assembly distinction not structurally defined","How the same subunit partitions between activating and repressive complexes unresolved"]},{"year":2017,"claim":"Provided structural basis for SMARCB1's interaction with the complex and dissected lineage-specific tumor outcomes.","evidence":"Crystal structure of BAF155 SWIRM–BAF47 RPT1 with ITC and NMR validation; stage- and lineage-specific conditional knockout mice generating rhabdoid tumors vs schwannomas","pmids":["28438634","28824165"],"confidence":"High","gaps":["Structure of the full SMARCB1 within the assembled complex not resolved","Molecular determinants linking developmental stage to tumor type unknown"]},{"year":2019,"claim":"Defined SMARCB1's role in development as a repressor of bivalent genes and super-enhancers required specifically for neural induction.","evidence":"SMARCB1 loss-of-function in hESCs and iPSCs with ChIP-seq, ATAC-seq, directed differentiation, and cerebral organoids showing differentiation-state-dependent effects","pmids":["31033435","32912900"],"confidence":"High","gaps":["Mechanism of cell-type-selective requirement unresolved","How super-enhancer silencing is enforced by SMARCB1 not defined"]},{"year":2020,"claim":"Identified IL6/JAK/STAT3 as a SMARCB1-deficiency vulnerability and SMARCB1 as a direct IL6 promoter repressor, linking chromatin accessibility changes to a druggable signaling axis.","evidence":"ATAC-seq, ChIP at IL6 promoter, loss/gain-of-function, orthotopic xenografts and PDX with STAT3 inhibitor TTI-101; NUP210 enhancer ChIP-seq in liver cancer","pmids":["38355560","32492816","33239431"],"confidence":"High","gaps":["Whether STAT3 activation is uniform across SMARCB1-deficient tumor types untested","Context-dependent up- vs down-regulation by SMARCB1 not mechanistically unified"]},{"year":2021,"claim":"Solved how SMARCB1 modulates HIV-1 integrase by showing the Rpt1 domain structurally mimics TAR RNA and competes for integrase binding.","evidence":"NMR structure of INI1 Rpt1, mutational analysis, competition binding (IC50), and computational modeling of the IN-CTD interface","pmids":["33980829"],"confidence":"High","gaps":["Physiological relevance during natural infection not established","Link between integrase-binding and SWI/SNF chromatin function unexplored"]},{"year":2023,"claim":"Showed SMARCB1 reshapes 3D enhancer architecture and reverses oncogenic transcriptional switches, including MYC enhancer looping and a MYC/ferroptosis-resistance program in renal medullary carcinoma.","evidence":"Patient-derived organoid multi-omics, chromosome conformation capture, single-cell RNA/ATAC-seq, SMARCB1 re-expression, ferroptosis assays, and hypoxia-induced SMARCB1 degradation in renal cells and a sickle cell trait mouse model","pmids":["38040699","37236926","37186844"],"confidence":"High","gaps":["Patient-specific enhancer heterogeneity mechanism unresolved","Pathway linking hypoxia to SMARCB1 degradation not fully defined"]},{"year":2024,"claim":"Reframed SMARCB1-mutant cancer as a consequence of DCAF5-mediated degradation of residual SWI/SNF complexes, and identified CBP/p300-driven KREMEN2 as a selective vulnerability.","evidence":"Genome-wide CRISPR screen, DCAF5 depletion, ChIP-seq, and in vivo xenografts; synthetic-lethal screen with H3K27ac/CBP/p300 ChIP-seq and CBP/p300 inhibition at the KREMEN2 locus","pmids":["38538798","38839769"],"confidence":"High","gaps":["How DCAF5 recognizes incompletely assembled complexes structurally undefined","Generalizability of KREMEN2 vulnerability across SMARCB1-deficient tumors untested"]},{"year":null,"claim":"How SMARCB1 mechanistically couples its structural role in BAF complex stabilization to the diverse target-gene programs (cyclin D1, p16, PLK1, IL6, MYC) and how this is read out in a cell-type- and developmental-stage-specific manner remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model of SMARCB1 within the assembled complex on chromatin","Determinants of lineage-specific target selection unknown","Reconciliation of SMARCB1 as both activator and repressor at different loci incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,11,25,28]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[12]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,17]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[2,17]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[12,19]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[0,17]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[19]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,17,22]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,11,25]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[2,3,11]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[21,28,31]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[21,22,23]}],"complexes":["SWI/SNF (BAF)","PBAF","N-CoR-1 repressor complex"],"partners":["SMARCC1","BRM/BRG1","DCAF5","MYOD","NUP210","HIV-1 INTEGRASE","LEDGF/P75"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q12824","full_name":"SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1","aliases":["BRG1-associated factor 47","BAF47","Integrase interactor 1 protein","SNF5 homolog","hSNF5"],"length_aa":385,"mass_kda":44.1,"function":"Core component of the BAF (hSWI/SNF) complex. This ATP-dependent chromatin-remodeling complex plays important roles in cell proliferation and differentiation, in cellular antiviral activities and inhibition of tumor formation. The BAF complex is able to create a stable, altered form of chromatin that constrains fewer negative supercoils than normal. This change in supercoiling would be due to the conversion of up to one-half of the nucleosomes on polynucleosomal arrays into asymmetric structures, termed altosomes, each composed of 2 histones octamers. Stimulates in vitro the remodeling activity of SMARCA4/BRG1/BAF190A. Involved in activation of CSF1 promoter. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity). Plays a key role in cell-cycle control and causes cell cycle arrest in G0/G1","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q12824/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/SMARCB1","classification":"Common Essential","n_dependent_lines":1005,"n_total_lines":1208,"dependency_fraction":0.831953642384106},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000099956","cell_line_id":"CID001676","localizations":[{"compartment":"nucleoplasm","grade":3},{"compartment":"chromatin","grade":2}],"interactors":[{"gene":"ARID1A","stoichiometry":10.0},{"gene":"ARID1B","stoichiometry":10.0},{"gene":"PHF10","stoichiometry":10.0},{"gene":"SMARCA2","stoichiometry":10.0},{"gene":"SMARCA4","stoichiometry":10.0},{"gene":"SMARCC1","stoichiometry":10.0},{"gene":"SMARCE1","stoichiometry":10.0},{"gene":"SMARCD1","stoichiometry":10.0},{"gene":"SMARCC2","stoichiometry":10.0},{"gene":"DPF2","stoichiometry":10.0}],"url":"https://opencell.sf.czbiohub.org/target/CID001676","total_profiled":1310},"omim":[{"mim_id":"617768","title":"KLEEFSTRA SYNDROME 2; KLEFS2","url":"https://www.omim.org/entry/617768"},{"mim_id":"616938","title":"COFFIN-SIRIS SYNDROME 5; CSS5","url":"https://www.omim.org/entry/616938"},{"mim_id":"616333","title":"WNT SIGNALING PATHWAY ACTIVATING NONCODING RNA; WSPAR","url":"https://www.omim.org/entry/616333"},{"mim_id":"615873","title":"HELSMOORTEL-VAN DER AA SYNDROME; HVDAS","url":"https://www.omim.org/entry/615873"},{"mim_id":"615670","title":"SCHWANNOMATOSIS 2; SWN2","url":"https://www.omim.org/entry/615670"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli fibrillar center","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SMARCB1"},"hgnc":{"alias_symbol":["BAF47","Ini1","INI-1","Snr1","hSNFS","Sfh1p","RDT","PPP1R144","SNF5"],"prev_symbol":["SNF5L1"]},"alphafold":{"accession":"Q12824","domains":[{"cath_id":"-","chopping":"15-106","consensus_level":"high","plddt":83.34,"start":15,"end":106},{"cath_id":"-","chopping":"260-331_342-379","consensus_level":"medium","plddt":88.8443,"start":260,"end":379}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q12824","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q12824-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q12824-F1-predicted_aligned_error_v6.png","plddt_mean":80.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SMARCB1","jax_strain_url":"https://www.jax.org/strain/search?query=SMARCB1"},"sequence":{"accession":"Q12824","fasta_url":"https://rest.uniprot.org/uniprotkb/Q12824.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q12824/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q12824"}},"corpus_meta":[{"pmid":"9892189","id":"PMC_9892189","title":"Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9892189","citation_count":692,"is_preprint":false},{"pmid":"33035459","id":"PMC_33035459","title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.","date":"2020","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33035459","citation_count":328,"is_preprint":false},{"pmid":"21934399","id":"PMC_21934399","title":"INI1-deficient tumors: diagnostic features and molecular genetics.","date":"2011","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21934399","citation_count":319,"is_preprint":false},{"pmid":"17357086","id":"PMC_17357086","title":"Germline mutation of INI1/SMARCB1 in familial schwannomatosis.","date":"2007","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17357086","citation_count":277,"is_preprint":false},{"pmid":"21108436","id":"PMC_21108436","title":"Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors.","date":"2011","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21108436","citation_count":271,"is_preprint":false},{"pmid":"15899790","id":"PMC_15899790","title":"SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15899790","citation_count":262,"is_preprint":false},{"pmid":"28945250","id":"PMC_28945250","title":"SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters.","date":"2017","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28945250","citation_count":226,"is_preprint":false},{"pmid":"9539705","id":"PMC_9539705","title":"The C-terminal SET domains of ALL-1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9539705","citation_count":205,"is_preprint":false},{"pmid":"7579694","id":"PMC_7579694","title":"The Drosophila snr1 and brm proteins are related to yeast SWI/SNF proteins and are components of a large protein complex.","date":"1995","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/7579694","citation_count":199,"is_preprint":false},{"pmid":"12138206","id":"PMC_12138206","title":"Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12138206","citation_count":194,"is_preprint":false},{"pmid":"28291122","id":"PMC_28291122","title":"SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity.","date":"2017","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28291122","citation_count":188,"is_preprint":false},{"pmid":"12149641","id":"PMC_12149641","title":"Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12149641","citation_count":173,"is_preprint":false},{"pmid":"28109176","id":"PMC_28109176","title":"Oncogenic roles of SMARCB1/INI1 and its deficient tumors.","date":"2017","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/28109176","citation_count":164,"is_preprint":false},{"pmid":"19305156","id":"PMC_19305156","title":"The role of SMARCB1/INI1 in development of rhabdoid tumor.","date":"2009","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19305156","citation_count":158,"is_preprint":false},{"pmid":"25007146","id":"PMC_25007146","title":"SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract.","date":"2014","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25007146","citation_count":153,"is_preprint":false},{"pmid":"21057957","id":"PMC_21057957","title":"Loss of SMARCB1/INI1 expression in poorly differentiated chordomas.","date":"2010","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/21057957","citation_count":152,"is_preprint":false},{"pmid":"18285426","id":"PMC_18285426","title":"Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis.","date":"2008","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18285426","citation_count":152,"is_preprint":false},{"pmid":"25299309","id":"PMC_25299309","title":"The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity.","date":"2014","source":"Advances in anatomic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25299309","citation_count":135,"is_preprint":false},{"pmid":"24832165","id":"PMC_24832165","title":"SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms.","date":"2014","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24832165","citation_count":129,"is_preprint":false},{"pmid":"24853101","id":"PMC_24853101","title":"Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.","date":"2014","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24853101","citation_count":117,"is_preprint":false},{"pmid":"18647326","id":"PMC_18647326","title":"Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis.","date":"2008","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18647326","citation_count":116,"is_preprint":false},{"pmid":"20305614","id":"PMC_20305614","title":"Reduced expression of SMARCB1/INI1 protein in synovial sarcoma.","date":"2010","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/20305614","citation_count":98,"is_preprint":false},{"pmid":"24503755","id":"PMC_24503755","title":"SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review.","date":"2014","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24503755","citation_count":97,"is_preprint":false},{"pmid":"29280680","id":"PMC_29280680","title":"SMARCB1-deficient Tumors of Childhood: A Practical Guide.","date":"2017","source":"Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society","url":"https://pubmed.ncbi.nlm.nih.gov/29280680","citation_count":91,"is_preprint":false},{"pmid":"17717433","id":"PMC_17717433","title":"Immunohistochemistry of INI1 expression: a new tool for old challenges in CNS and soft tissue pathology.","date":"2007","source":"Advances in anatomic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17717433","citation_count":85,"is_preprint":false},{"pmid":"37228094","id":"PMC_37228094","title":"Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.","date":"2023","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/37228094","citation_count":83,"is_preprint":false},{"pmid":"10602515","id":"PMC_10602515","title":"Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10602515","citation_count":79,"is_preprint":false},{"pmid":"28824165","id":"PMC_28824165","title":"Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28824165","citation_count":79,"is_preprint":false},{"pmid":"24933152","id":"PMC_24933152","title":"SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors.","date":"2014","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24933152","citation_count":79,"is_preprint":false},{"pmid":"15150092","id":"PMC_15150092","title":"The tumor suppressor hSNF5/INI1 modulates cell growth and actin cytoskeleton organization.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15150092","citation_count":76,"is_preprint":false},{"pmid":"29440190","id":"PMC_29440190","title":"A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29440190","citation_count":71,"is_preprint":false},{"pmid":"25246033","id":"PMC_25246033","title":"Pathology and diagnosis of SMARCB1-deficient tumors.","date":"2014","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25246033","citation_count":66,"is_preprint":false},{"pmid":"26941181","id":"PMC_26941181","title":"Gene of the month: SMARCB1.","date":"2016","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26941181","citation_count":63,"is_preprint":false},{"pmid":"30619149","id":"PMC_30619149","title":"Anti-inflammatory and Antioxidant Properties of Probiotic Bacterium Lactobacillus mucosae AN1 and Lactobacillus fermentum SNR1 in Wistar Albino Rats.","date":"2018","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/30619149","citation_count":62,"is_preprint":false},{"pmid":"27635948","id":"PMC_27635948","title":"SMARCB1/INI1 Involvement in Pediatric Chordoma: A Mutational and Immunohistochemical Analysis.","date":"2017","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27635948","citation_count":58,"is_preprint":false},{"pmid":"22260386","id":"PMC_22260386","title":"p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.","date":"2012","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/22260386","citation_count":57,"is_preprint":false},{"pmid":"29309303","id":"PMC_29309303","title":"SWI/SNF Chromatin-remodeling Complex Status in SMARCB1/INI1-preserved Epithelioid Sarcoma.","date":"2018","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29309303","citation_count":55,"is_preprint":false},{"pmid":"30864974","id":"PMC_30864974","title":"Recurrent SMARCB1 Inactivation in Epithelioid Malignant Peripheral Nerve Sheath Tumors.","date":"2019","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30864974","citation_count":54,"is_preprint":false},{"pmid":"30120966","id":"PMC_30120966","title":"SMARCB1 (INI1)-deficient sinonasal carcinoma: a series of 13 cases with assessment of histologic patterns.","date":"2018","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30120966","citation_count":54,"is_preprint":false},{"pmid":"28368924","id":"PMC_28368924","title":"SMARCB1/INI1 Loss in Epithelioid Schwannoma: A Clinicopathologic and Immunohistochemical Study of 65 Cases.","date":"2017","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28368924","citation_count":53,"is_preprint":false},{"pmid":"31468350","id":"PMC_31468350","title":"SMARCB1 (INI-1)-Deficient Adenocarcinoma of the Sinonasal Tract: A Potentially Under-Recognized form of Sinonasal Adenocarcinoma with Occasional Yolk Sac Tumor-Like Features.","date":"2019","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31468350","citation_count":51,"is_preprint":false},{"pmid":"26407663","id":"PMC_26407663","title":"Reappraisal of sinonasal undifferentiated carcinoma: SMARCB1 (INI1)-deficient sinonasal carcinoma: a single-institution experience.","date":"2015","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26407663","citation_count":51,"is_preprint":false},{"pmid":"38538798","id":"PMC_38538798","title":"Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF.","date":"2024","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/38538798","citation_count":49,"is_preprint":false},{"pmid":"12645932","id":"PMC_12645932","title":"SNR1 is an essential subunit in a subset of Drosophila brm complexes, targeting specific functions during development.","date":"2003","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/12645932","citation_count":48,"is_preprint":false},{"pmid":"22949514","id":"PMC_22949514","title":"Expression of SMARCB1 (INI1) mutations in familial schwannomatosis.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22949514","citation_count":47,"is_preprint":false},{"pmid":"12082626","id":"PMC_12082626","title":"Chromatin remodeling factor encoded by ini1 induces G1 arrest and apoptosis in ini1-deficient cells.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12082626","citation_count":44,"is_preprint":false},{"pmid":"32122923","id":"PMC_32122923","title":"Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/32122923","citation_count":42,"is_preprint":false},{"pmid":"32912900","id":"PMC_32912900","title":"SMARCB1 loss interacts with neuronal differentiation state to block maturation and impact cell stability.","date":"2020","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/32912900","citation_count":40,"is_preprint":false},{"pmid":"21705046","id":"PMC_21705046","title":"Immunohistochemical analysis of SMARCB1/INI-1 expression in collecting duct carcinoma.","date":"2011","source":"Urology","url":"https://pubmed.ncbi.nlm.nih.gov/21705046","citation_count":38,"is_preprint":false},{"pmid":"23576573","id":"PMC_23576573","title":"SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJ.","date":"2013","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23576573","citation_count":38,"is_preprint":false},{"pmid":"17699849","id":"PMC_17699849","title":"INI1 induces interferon signaling and spindle checkpoint in rhabdoid tumors.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17699849","citation_count":37,"is_preprint":false},{"pmid":"31033435","id":"PMC_31033435","title":"Tumor suppressor SMARCB1 suppresses super-enhancers to govern hESC lineage determination.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31033435","citation_count":35,"is_preprint":false},{"pmid":"22467207","id":"PMC_22467207","title":"The chromatin remodeling and mRNA splicing functions of the Brahma (SWI/SNF) complex are mediated by the SNR1/SNF5 regulatory subunit.","date":"2012","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/22467207","citation_count":35,"is_preprint":false},{"pmid":"38355560","id":"PMC_38355560","title":"The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38355560","citation_count":34,"is_preprint":false},{"pmid":"12482982","id":"PMC_12482982","title":"The Drosophila SNR1 (SNF5/INI1) subunit directs essential developmental functions of the Brahma chromatin remodeling complex.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12482982","citation_count":34,"is_preprint":false},{"pmid":"16945155","id":"PMC_16945155","title":"HIV-1 replication in cell lines harboring INI1/hSNF5 mutations.","date":"2006","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/16945155","citation_count":30,"is_preprint":false},{"pmid":"11104031","id":"PMC_11104031","title":"HSNF5/INI1 gene mutations in lymphoid malignancy.","date":"2000","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11104031","citation_count":30,"is_preprint":false},{"pmid":"37236926","id":"PMC_37236926","title":"SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37236926","citation_count":29,"is_preprint":false},{"pmid":"38040699","id":"PMC_38040699","title":"SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38040699","citation_count":29,"is_preprint":false},{"pmid":"28438634","id":"PMC_28438634","title":"Structural Insights into BAF47 and BAF155 Complex Formation.","date":"2017","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28438634","citation_count":29,"is_preprint":false},{"pmid":"25912315","id":"PMC_25912315","title":"Utility of characteristic 'Weak to Absent' INI1/SMARCB1/BAF47 expression in diagnosis of synovial sarcomas.","date":"2015","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/25912315","citation_count":29,"is_preprint":false},{"pmid":"19318800","id":"PMC_19318800","title":"INI1 and GLUT-1 expression in epithelioid sarcoma and its cutaneous neoplastic and nonneoplastic mimics.","date":"2009","source":"The American Journal of dermatopathology","url":"https://pubmed.ncbi.nlm.nih.gov/19318800","citation_count":29,"is_preprint":false},{"pmid":"23851500","id":"PMC_23851500","title":"Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23851500","citation_count":29,"is_preprint":false},{"pmid":"31273213","id":"PMC_31273213","title":"Mutations in SMARCB1 and in other Coffin-Siris syndrome genes lead to various brain midline defects.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31273213","citation_count":29,"is_preprint":false},{"pmid":"23593299","id":"PMC_23593299","title":"Structural and functional role of INI1 and LEDGF in the HIV-1 preintegration complex.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23593299","citation_count":29,"is_preprint":false},{"pmid":"33239431","id":"PMC_33239431","title":"Nucleoporin 210 Serves a Key Scaffold for SMARCB1 in Liver Cancer.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33239431","citation_count":27,"is_preprint":false},{"pmid":"33796273","id":"PMC_33796273","title":"SMARCB1/INI1-deficient tumors of adulthood.","date":"2020","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/33796273","citation_count":25,"is_preprint":false},{"pmid":"19398554","id":"PMC_19398554","title":"Multimerization and DNA binding properties of INI1/hSNF5 and its functional significance.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19398554","citation_count":24,"is_preprint":false},{"pmid":"37186844","id":"PMC_37186844","title":"SMARCB1 regulates the hypoxic stress response in sickle cell trait.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37186844","citation_count":23,"is_preprint":false},{"pmid":"16671894","id":"PMC_16671894","title":"dDYRK2 and Minibrain interact with the chromatin remodelling factors SNR1 and TRX.","date":"2006","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/16671894","citation_count":23,"is_preprint":false},{"pmid":"15454538","id":"PMC_15454538","title":"SNR1 (INI1/SNF5) mediates important cell growth functions of the Drosophila Brahma (SWI/SNF) chromatin remodeling complex.","date":"2004","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15454538","citation_count":23,"is_preprint":false},{"pmid":"36088476","id":"PMC_36088476","title":"The genetic landscape of SMARCB1 alterations in SMARCB1-deficient spectrum of mesenchymal neoplasms.","date":"2022","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/36088476","citation_count":23,"is_preprint":false},{"pmid":"23161234","id":"PMC_23161234","title":"Specificity and sensitivity of INI-1 labeling in epithelioid sarcoma. Loss of INI1 expression as a frequent immunohistochemical event in synovial sarcoma.","date":"2012","source":"Polish journal of pathology : official journal of the Polish Society of Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/23161234","citation_count":21,"is_preprint":false},{"pmid":"25271443","id":"PMC_25271443","title":"The SWI/SNF subunit/tumor suppressor BAF47/INI1 is essential in cell cycle arrest upon skeletal muscle terminal differentiation.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25271443","citation_count":20,"is_preprint":false},{"pmid":"32818509","id":"PMC_32818509","title":"Genetic basis of SMARCB1 protein loss in 22 sinonasal carcinomas.","date":"2020","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32818509","citation_count":20,"is_preprint":false},{"pmid":"32910019","id":"PMC_32910019","title":"BRG1, INI1, and ARID1B Deficiency in Endometrial Carcinoma: A Clinicopathologic and Immunohistochemical Analysis of a Large Series From a Single Institution.","date":"2020","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32910019","citation_count":20,"is_preprint":false},{"pmid":"17040295","id":"PMC_17040295","title":"SMARCB1/INI1 missense mutation in mucinous carcinoma with rhabdoid features.","date":"2006","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/17040295","citation_count":20,"is_preprint":false},{"pmid":"33141418","id":"PMC_33141418","title":"SMARCB1/INI1 Deficient Sino-Nasal Carcinoma: Extending the Histomorphological Features.","date":"2020","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33141418","citation_count":19,"is_preprint":false},{"pmid":"33980829","id":"PMC_33980829","title":"INI1/SMARCB1 Rpt1 domain mimics TAR RNA in binding to integrase to facilitate HIV-1 replication.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33980829","citation_count":19,"is_preprint":false},{"pmid":"19234532","id":"PMC_19234532","title":"The role of INI1/hSNF5 in gene regulation and cancer.","date":"2009","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/19234532","citation_count":19,"is_preprint":false},{"pmid":"34265804","id":"PMC_34265804","title":"Vulvar Yolk Sac Tumors Are Somatically Derived SMARCB1 (INI-1)-Deficient Neoplasms.","date":"2022","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34265804","citation_count":19,"is_preprint":false},{"pmid":"27177850","id":"PMC_27177850","title":"Cytopathologic characteristics of SMARCB1 (INI-1) deficient sinonasal carcinoma: A potential diagnostic pitfall.","date":"2016","source":"Diagnostic cytopathology","url":"https://pubmed.ncbi.nlm.nih.gov/27177850","citation_count":19,"is_preprint":false},{"pmid":"33824593","id":"PMC_33824593","title":"Case Report: SMARCB1 (INI-1)-Deficient Carcinoma of the Nasal Cavity with Pure Yolk Sac Tumor Differentiation and Elevated Serum AFP Levels.","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33824593","citation_count":19,"is_preprint":false},{"pmid":"35864317","id":"PMC_35864317","title":"Molecular and immunophenotypic characterization of SMARCB1 (INI1) - deficient intrathoracic Neoplasms.","date":"2022","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/35864317","citation_count":18,"is_preprint":false},{"pmid":"27923836","id":"PMC_27923836","title":"The SWI/SNF Complex Protein Snr1 Is a Tumor Suppressor in Drosophila Imaginal Tissues.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27923836","citation_count":18,"is_preprint":false},{"pmid":"37541451","id":"PMC_37541451","title":"Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors.","date":"2023","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37541451","citation_count":18,"is_preprint":false},{"pmid":"32337786","id":"PMC_32337786","title":"INI-1 (SMARCB1)-Deficient Undifferentiated Sinonasal Carcinoma: Novel Paradigm of Molecular Testing in the Diagnosis and Management of Sinonasal Malignancies.","date":"2020","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/32337786","citation_count":18,"is_preprint":false},{"pmid":"29228610","id":"PMC_29228610","title":"Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29228610","citation_count":17,"is_preprint":false},{"pmid":"34392582","id":"PMC_34392582","title":"Recurrent loss of chromosome 22 and SMARCB1 deletion in extra-axial chordoma: A clinicopathological and molecular analysis.","date":"2021","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34392582","citation_count":17,"is_preprint":false},{"pmid":"35257325","id":"PMC_35257325","title":"SMARCB1 (INI1)-Deficient Sinonasal Carcinoma with Yolk Sac differentiation Showing Co-loss of SMARCA4 Immunostaining - A Case Report and Literature Review.","date":"2022","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35257325","citation_count":17,"is_preprint":false},{"pmid":"29797680","id":"PMC_29797680","title":"Cytopathologic features of SMARCB1 (INI-1)-deficient sinonasal carcinoma.","date":"2018","source":"Cancer cytopathology","url":"https://pubmed.ncbi.nlm.nih.gov/29797680","citation_count":15,"is_preprint":false},{"pmid":"7627549","id":"PMC_7627549","title":"HIV integration. Ini1 for integration?","date":"1995","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/7627549","citation_count":15,"is_preprint":false},{"pmid":"35804041","id":"PMC_35804041","title":"Primary adult sellar SMARCB1/INI1-deficient tumor represents a subtype of atypical teratoid/rhabdoid tumor.","date":"2022","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/35804041","citation_count":14,"is_preprint":false},{"pmid":"35252869","id":"PMC_35252869","title":"Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells.","date":"2022","source":"NAR cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35252869","citation_count":14,"is_preprint":false},{"pmid":"38839769","id":"PMC_38839769","title":"Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38839769","citation_count":13,"is_preprint":false},{"pmid":"33581550","id":"PMC_33581550","title":"SMARCA4 (BRG1) and SMARCB1 (INI1) expression in TTF-1 negative neuroendocrine carcinomas including merkel cell carcinoma.","date":"2021","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/33581550","citation_count":13,"is_preprint":false},{"pmid":"29363919","id":"PMC_29363919","title":"EWSR1-fusion-negative, SMARCB1-deficient primary pulmonary myxoid sarcoma.","date":"2017","source":"Polish journal of pathology : official journal of the Polish Society of Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/29363919","citation_count":13,"is_preprint":false},{"pmid":"33024402","id":"PMC_33024402","title":"SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma mimicking solid pseudopapillary neoplasm: A case report and review of the literature.","date":"2020","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/33024402","citation_count":12,"is_preprint":false},{"pmid":"32492816","id":"PMC_32492816","title":"SMARCB1 Acts as a Quiescent Gatekeeper for Cell Cycle and Immune Response in Human Cells.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32492816","citation_count":12,"is_preprint":false},{"pmid":"29316066","id":"PMC_29316066","title":"SMARCB1/INI1/BAF47- deficient pleural malignant mesothelioma with rhabdoid features.","date":"2018","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/29316066","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53926,"output_tokens":8901,"usd":0.147647,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18813,"output_tokens":5790,"usd":0.119407,"stage2_stop_reason":"end_turn"},"total_usd":0.267054,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"Drosophila SNR1 (ortholog of human SMARCB1/INI1) physically associates with the Brahma (BRM) protein and is a component of a large (>2×10^6 Da) SWI/SNF-like chromatin-remodeling complex in Drosophila, as demonstrated by co-immunoprecipitation from fly extracts. SNR1 and BRM genetically interact with trithorax (trx), supporting a cooperative role in maintaining homeotic gene transcription.\",\n      \"method\": \"Co-immunoprecipitation from Drosophila extracts; genetic interaction analysis; biochemical fractionation\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus genetic epistasis, replicated across multiple studies in the field\",\n      \"pmids\": [\"7579694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The C-terminal SET domain of ALL-1 (human) and TRITHORAX (Drosophila) physically interact with INI1/hSNF5 (human) and SNR1 (Drosophila), respectively. Interaction was demonstrated by yeast two-hybrid, in vitro binding assays, and co-immunoprecipitation from cultured cells and transgenic flies. SNR1 co-localizes with ~half of TRX binding sites on polytene chromosomes, suggesting SWI/SNF recruitment to ALL-1/TRX target loci via these physical contacts.\",\n      \"method\": \"Yeast two-hybrid screen; in vitro pulldown; co-immunoprecipitation from cells and transgenic flies; polytene chromosome immunostaining\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (Y2H + in vitro binding + Co-IP + localization), confirmed in two species\",\n      \"pmids\": [\"9539705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Re-expression of INI1/hSNF5 in INI1-deficient rhabdoid tumor cells (MON) causes G0/G1 cell cycle arrest and flat cell formation. INI1 directly represses cyclin D1 transcription in an HDAC-dependent manner: chromatin immunoprecipitation showed INI1 is recruited to the cyclin D1 promoter, correlating with HDAC1 recruitment and histone deacetylation at that promoter. Ectopic cyclin D1 expression from a heterologous promoter rescued the INI1-mediated arrest.\",\n      \"method\": \"Retroviral re-expression; flow cytometry; ChIP; HDAC inhibitor experiments; rescue with ectopic cyclin D1; truncation analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct ChIP at cyclin D1 promoter, HDAC dependence, functional rescue, multiple orthogonal approaches in one study\",\n      \"pmids\": [\"12138206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Re-expression of hSNF5/INI1/BAF47 in INI1-deficient rhabdoid tumor cell lines induces G1 arrest associated with strong induction of p16ink4a and hypophosphorylation (activation) of RB, establishing that hSNF5 signals upstream of RB to induce growth arrest. Co-expression of SV40 T/t antigen or HPV-16 E7 (which inactivates RB) abrogated hSNF5-induced arrest.\",\n      \"method\": \"Retroviral re-expression; flow cytometry; Western blot; rescue with SV40 T/t or HPV E7\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean re-expression in multiple cell lines with epistatic rescue experiments validating p16-RB pathway placement\",\n      \"pmids\": [\"12149641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Re-introduction of INI1 into INI1-deficient cells causes G1 arrest and apoptosis (detected by cleaved PARP). Deletion analysis identified Repeats 1 and 2 of INI1 as required for growth suppression in a colony formation assay.\",\n      \"method\": \"Recombinant adenovirus-mediated overexpression; flow cytometry; BrdU incorporation; colony formation; PARP cleavage assay; deletion mutagenesis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — functional domain mapping by mutagenesis plus multiple cell-biological readouts in single study\",\n      \"pmids\": [\"12082626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Drosophila SNR1 is an essential but tissue-selective subunit of the Brm (SWI/SNF) complex. A temperature-sensitive allele (snr1E1) with a single amino acid substitution in the conserved Repeat 2 region reduces Brm complex function. SNR1 can make direct contacts through its Repeat 2 region with the SET domain of Trithorax (TRX), and snr1E1 is partially defective for TRX association, establishing Repeat 2 as critical for protein–protein interaction and growth control.\",\n      \"method\": \"Genetic allele analysis; temperature-shift experiments; Co-IP; in vitro binding; polytene chromosome immunostaining\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic + biochemical + structural domain mapping with multiple orthogonal methods\",\n      \"pmids\": [\"12482982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Drosophila SNR1 is required for a subset of Brm complex functions in vivo; SNR1-deficient imaginal tissues show altered gene expression patterns. Genome-wide localization shows SNR1 and BRM co-occupy many chromosomal loci but SNR1 is not required in all tissues dependent on BRM, indicating SNR1 acts as an optional subunit directing complex activity to specific loci.\",\n      \"method\": \"Genetic loss-of-function analysis; polytene chromosome immunostaining; in vivo somatic clone analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic analysis plus localization in single organism, no direct biochemical reconstitution\",\n      \"pmids\": [\"12645932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Re-induction of hSNF5/INI1 in rhabdoid tumor cells leads to reversible G1 arrest, down-regulation of DNA replication complex components, and dramatic reorganization of the actin cytoskeleton including disruption of actin stress fibers and focal adhesions. INI1 induction strongly decreases RhoA GTPase activity, suggesting that INI1 regulates actin organization through the Rho pathway.\",\n      \"method\": \"Tetracycline-inducible expression system; genome-wide microarray (22,000 genes); estrogen receptor fusion to identify direct targets; Rho activity assay; cell morphology imaging\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genome-wide target identification combined with functional Rho activity assay and direct-target fusion protein approach in one rigorous study\",\n      \"pmids\": [\"15150092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In Drosophila, SNR1 mediates associations between the Brm chromatin-remodeling complex and CyclinE/CDK2 both in vitro and in vivo. Disruption of snr1 suppresses DmcycE phenotypes and loss of snr1 function reduces transcription of the G2-M regulator string/cdc25, implicating SNR1 in G1-S control and G2-M progression.\",\n      \"method\": \"In vitro binding assay; genetic epistasis (double mutant analysis); transcription assay\",\n      \"journal\": \"Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro interaction plus genetic epistasis, Drosophila ortholog study\",\n      \"pmids\": [\"15454538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Drosophila DYRK2 (dDYRK2) and Minibrain (MNB) interact with SNR1 (the SMARCB1 ortholog) as demonstrated by yeast two-hybrid and co-immunoprecipitation. Both kinases phosphorylate SNR1 at Thr102 in vitro and in vivo, representing the first identified phosphorylation of SNR1 or its homologs.\",\n      \"method\": \"Yeast two-hybrid; co-immunoprecipitation; in vitro kinase assay; in vivo phosphorylation\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphorylation confirmed both in vitro and in vivo in single study, Drosophila ortholog\",\n      \"pmids\": [\"16671894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"INI1 is specifically incorporated into HIV-1 virions. In INI1-deficient cells, HIV-1 particle production is severely reduced and infectivity is impaired; re-introduction of INI1 rescues particle production. Virions produced from INI1-null cells are defective for early and late reverse transcription products and for exogenous reverse transcriptase activity.\",\n      \"method\": \"HIV-1 infection of INI1-deficient rhabdoid cell lines; retroviral re-expression; RT assay; transduction assay\",\n      \"journal\": \"Retrovirology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional virology experiments in INI1-null lines with rescue; single lab\",\n      \"pmids\": [\"16945155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Re-introduction of INI1 into rhabdoid cells activates interferon-stimulated genes at early time points, senescence markers at late time points, and represses mitotic genes including PLK1. RNAi knockdown of PLK1 in INI1-deficient rhabdoid cells causes mitotic arrest, aberrant nuclear division, and apoptosis, establishing PLK1 as a functionally relevant downstream effector of INI1.\",\n      \"method\": \"cDNA microarray; qRT-PCR; Western blot; IHC of primary tumors; RNAi knockdown; cell cycle/apoptosis assays; IFN treatment\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide target identification confirmed by RNAi functional epistasis and primary tumor validation; multiple methods\",\n      \"pmids\": [\"17699849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"INI1/hSNF5 forms multimeric structures; the Rpt1 and Rpt2 motifs constitute the minimal multimerization domain. Multimerization-defective mutants (identified by reverse yeast two-hybrid) are defective for nuclear retention, co-localization with HIV-1 integrase, and the transdominant inhibitory effect of the S6 fragment on HIV-1. INI1 also binds DNA in the minor groove; acceptor DNA binding may be required for stimulation of in vitro strand transfer by integrase.\",\n      \"method\": \"Protein purification; reverse yeast two-hybrid; deletion analysis; co-immunoprecipitation; in vitro strand transfer assay; nuclear localization imaging\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with mutagenesis, multiple biochemical assays in single rigorous study\",\n      \"pmids\": [\"19398554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The SNR1/SNF5 subunit of the Drosophila Brm (SWI/SNF) complex controls RNA polymerase II elongation and pre-mRNA splicing at ecdysone-responsive genes. RNAi knockdown or conditional loss-of-function alleles show that a loss-of-function SNR1 subunit alters chromatin accessibility, RNA Pol II elongation, and splicing of specific hormone-regulated genes, restricting BRM-dependent nucleosome remodeling downstream of the promoter.\",\n      \"method\": \"RNAi knockdown in cultured Drosophila cells and transgenic flies; conditional mutant alleles; transcriptome profiling; chromatin accessibility assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with transcriptome readout and chromatin accessibility; Drosophila ortholog; single lab\",\n      \"pmids\": [\"22467207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Restoration of Smarcb1 in Smarcb1-deficient mouse tumor cells abolishes xenograft growth and restores sensitivity to apoptosis without inducing growth arrest in vitro. Smarcb1 is required for transcriptional activation of Igfbp7 (a tumor suppressor); Smarcb1-deficient cells show persistent PI3K-mediated AKT activation, and AKT inhibition reduces proliferation and xenograft growth. Re-introduction of Igfbp7 alone inhibits tumor development.\",\n      \"method\": \"Retroviral re-expression; xenograft assay; AKT inhibitor treatment; gene expression profiling; Igfbp7 rescue experiment\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo xenograft rescue plus epistatic Igfbp7 re-expression and pharmacological pathway validation\",\n      \"pmids\": [\"23851500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Restoration of SMARCB1 expression in epithelioid sarcoma cell line VAESBJ (which has a homozygous SMARCB1 deletion) significantly reduces cell proliferation, anchorage-independent growth, and cell migration, establishing a direct causal role for SMARCB1 loss in epithelioid sarcoma pathogenesis.\",\n      \"method\": \"SMARCB1 re-expression; colony formation; soft agar assay; wound-healing/migration assay\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean loss-of-function validated by re-expression with multiple cellular phenotype readouts; single lab\",\n      \"pmids\": [\"23576573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The INI1-Rpt1 integrase-binding domain (IBD) forms a stable complex with HIV-1 integrase (IN), LEDGF/p75, and viral U5 DNA at a stoichiometry of 4 IN:2 LEDGF:2 INI1-IBD:2 DNA determined by mass spectrometry and fluorescence correlation spectroscopy. INI1-IBD inhibits the 3' processing reaction but not specific viral DNA binding. Cryo-EM locates INI1-IBD within the cellular DNA-binding site of the IN/LEDGF complex, constraining IN in a stable conformation that prevents non-specific interactions.\",\n      \"method\": \"In vitro reconstitution of multiprotein complex; mass spectrometry stoichiometry; fluorescence correlation spectroscopy; in vitro integration/3'-processing assay; cryo-electron microscopy\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — cryo-EM structure plus in vitro reconstitution and functional assays; multiple orthogonal methods in one study\",\n      \"pmids\": [\"23593299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BAF47 (SMARCB1) loss destabilizes BAF complexes on chromatin without significantly altering complex assembly or integrity. Rescue of BAF47 in BAF47-deficient sarcoma cell lines increases genome-wide BAF complex occupancy (measured by ChIP-seq), leading to widespread enhancer activation and opposition of Polycomb-mediated repression at bivalent promoters. Two distinct mSWI/SNF assemblies (BAF and PBAF) differentially regulate enhancers and promoters, respectively.\",\n      \"method\": \"ChIP-seq for BAF complex occupancy; genome-wide enhancer and promoter analysis; re-expression of SMARCB1 in deficient cell lines\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genome-wide ChIP-seq with re-expression rescue, distinguishing two mSWI/SNF assemblies, single rigorous study with multiple orthogonal approaches\",\n      \"pmids\": [\"28945250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BAF47/INI1 interacts with MyoD and is part of both the SWI/SNF remodeling complex and the N-CoR-1 repressor complex in proliferating myoblasts. Upon myogenic differentiation, BAF47 shifts toward the N-CoR-1 complex. BAF47 downregulation disrupts both the proliferation and differentiation gene programs, and only BAF47 (not BRG1) is essential for irreversible cell cycle exit during myoblast terminal differentiation.\",\n      \"method\": \"Co-immunoprecipitation; siRNA knockdown; ChIP; gene expression analysis during differentiation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP complex identification plus functional knockdown with differentiation phenotype; single lab\",\n      \"pmids\": [\"25271443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In Drosophila imaginal epithelial tissues, Snr1 (SMARCB1 ortholog) prevents neoplastic overgrowth by maintaining normal endosomal trafficking-mediated signaling. Unlike loss of any other SWI/SNF subunit, snr1 depletion alone induces neoplastic tumorigenic overgrowth. Snr1 is found in both nucleus and cytoplasm, and its loss aberrantly activates Notch, JNK, and JAK/STAT signaling pathways.\",\n      \"method\": \"Genetic loss-of-function (tissue-specific RNAi/clones); immunofluorescence localization; pathway reporter assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with pathway epistasis in Drosophila ortholog; single lab\",\n      \"pmids\": [\"27923836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of the BAF155 SWIRM domain in complex with the BAF47 (SMARCB1) Repeat 1 (RPT1) domain was determined at high resolution. Extensive mutagenesis combined with isothermal titration calorimetry and NMR titrations confirmed the interface residues. The SWIRM domain of BAF155 is a modular domain responsible for interaction with BAF47, functionally distinct from DNA-binding SWIRM domains.\",\n      \"method\": \"X-ray crystallography; mutagenesis; isothermal titration calorimetry (ITC); NMR titration\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with mutagenesis and two independent biophysical validation methods (ITC + NMR)\",\n      \"pmids\": [\"28438634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Timing of Smarcb1 and Nf2 inactivation determines tumor type: early Smarcb1 loss in neural crest initiates rhabdoid tumors in cranial nerves and meninges, whereas Smarcb1 loss at a later stage in the Schwann cell lineage combined with biallelic Nf2 inactivation generates schwannomas. This establishes a developmental stage-specific and cell-type-specific mechanism governing the two distinct SMARCB1-associated tumor syndromes.\",\n      \"method\": \"Tissue- and developmental stage-specific conditional knockout mice; histological and molecular profiling of resulting tumors\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic epistasis with stage- and lineage-specific conditional knockouts, generating two distinct tumor types; rigorous mouse model study\",\n      \"pmids\": [\"28824165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In human embryonic stem cells (hESCs), SMARCB1 represses bivalent genes and antagonizes chromatin accessibility at super-enhancers. SMARCB1 is specifically required for neural induction but dispensable for mesodermal or endodermal differentiation, and is essential for super-enhancer silencing during neural differentiation conditions.\",\n      \"method\": \"SMARCB1 knockdown/loss-of-function in hESCs; ChIP-seq; ATAC-seq; directed differentiation assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide chromatin profiling (ChIP-seq, ATAC-seq) combined with directed differentiation lineage assays; multiple orthogonal approaches\",\n      \"pmids\": [\"31033435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SMARCB1 loss in an inducible iPSC-based system interacts with neural differentiation state to cause resistance to terminal differentiation and defects in maintenance of normal cell state. The downstream effects of SMARCB1 loss are substantially different depending on the differentiation state of the cell.\",\n      \"method\": \"Inducible SMARCB1 loss-of-function in human iPSCs; directed neuronal differentiation; cerebral organoid differentiation; transcriptomic analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible system in iPSCs with differentiation state comparison; single lab\",\n      \"pmids\": [\"32912900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SMARCB1 loss increases chromatin accessibility at the STAT3 locus in vitro, and SMARCB1 knockout cell lines show increased IL6/JAK/STAT3 signaling in orthotopic in vivo models. A pSTAT3 selective inhibitor (TTI-101) reduces tumor growth in SMARCB1 KO xenograft and patient-derived xenograft models, establishing the IL6/JAK/STAT3 axis as a SMARCB1-deficiency-driven vulnerability.\",\n      \"method\": \"SMARCB1 knockout; ATAC-seq; orthotopic xenograft models; pharmacological STAT3 inhibition; patient-derived xenograft\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ATAC-seq mechanistic link plus in vivo validation in multiple models including PDX; multiple orthogonal approaches\",\n      \"pmids\": [\"38355560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SMARCB1 directly binds the IL6 promoter in a steady state (ChIP), dissociates during immune activation, and acts as a direct transcriptional repressor of IL6. Loss- and gain-of-function studies confirm that SMARCB1 represses IL6 expression and loss of SMARCB1 reduces cell cycle progression via p21 upregulation.\",\n      \"method\": \"ChIP; loss- and gain-of-function (siRNA and overexpression); transcriptome analysis; flow cytometry\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP at IL6 promoter with functional rescue; single lab\",\n      \"pmids\": [\"32492816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SMARCB1 upregulation in liver cancer contributes to SWI/SNF complex stability. SMARCB1 binds the enhancer of NUP210 (Nucleoporin 210) and regulates H3K27Ac enrichment there, changing NUP210 downstream gene expression (including cholesterol homeostasis and xenobiotic metabolism). NUP210 acts as a key scaffold for SMARCB1 and P300 on chromatin.\",\n      \"method\": \"ChIP-seq for SMARCB1 and H3K27Ac; loss- and gain-of-function in liver cancer cells; in vivo tumor models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq identifying NUP210 as direct target with functional in vivo validation; single lab\",\n      \"pmids\": [\"33239431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NMR structure of the INI1/SMARCB1 Rpt1 domain and modeling of its interaction with the HIV-1 integrase C-terminal domain (IN-CTD) reveal that INI1-Rpt1 interface residues overlap with those required for IN/RNA interaction. INI1-Rpt1 and TAR RNA compete for IN binding with similar IC50 values. Computational modeling suggests INI1-Rpt1 structurally mimics TAR RNA at the interface, explaining how INI1 influences HIV-1 late events via integrase.\",\n      \"method\": \"NMR structure determination; mutational analysis; competition binding assays (IC50); computational modeling\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure plus mutagenesis and competition binding assays; single study with multiple orthogonal methods\",\n      \"pmids\": [\"33980829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SMARCB1 re-expression in renal medullary carcinoma (RMC) cells reverses a TFCP2L1→MYC transcriptional switch, repressing MYC and NFE2L2-associated oncogenic and ferroptosis-resistance programs, leading to ferroptotic cell death. SMARCB1 loss activates MYC and ferroptosis resistance programs in TAL (thick ascending limb) cell-derived RMC, linking SCT-associated hypoxia and iron environment to SMARCB1-mediated transformation.\",\n      \"method\": \"Single-cell RNA-seq of human RMC; SMARCB1 re-expression with transcriptomic analysis; ferroptosis assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — single-cell sequencing plus SMARCB1 re-expression with functional ferroptosis readout; multiple orthogonal methods\",\n      \"pmids\": [\"37236926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SMARCB1 loss in malignant rhabdoid tumors leads to dramatic reshaping of the regulatory landscape including patient-specific looping of distal enhancer regions with the MYC oncogene promoter (demonstrated by chromosome conformation capture). SMARCB1 reconstitution reverses this epigenetic reprogramming. Intertumoral heterogeneity in MYC enhancer utilization is present in patient tissues.\",\n      \"method\": \"Multi-omics on patient-derived MRT organoids; SMARCB1 re-expression; chromosome conformation capture (Hi-C/4C); single-cell RNA-seq; single-cell ATAC-seq on patient tissues\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — chromosome conformation capture plus single-cell multi-omics in organoids and patient tissues; multiple orthogonal approaches\",\n      \"pmids\": [\"38040699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Hypoxia induces SMARCB1 protein degradation in renal cells, protecting them from hypoxic stress. In a sickle cell trait mouse model, SMARCB1 wild-type renal tumors show lower SMARCB1 levels and more aggressive growth than controls; SMARCB1 reconstitution restores sensitivity to hypoxic stress in vitro and in vivo.\",\n      \"method\": \"In vitro hypoxia experiments; sickle cell trait mouse model; SMARCB1 re-expression; in vivo tumor growth assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo experiments with re-expression rescue; single lab\",\n      \"pmids\": [\"37186844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DCAF5 (a CUL4-DDB1 substrate receptor) functions as a quality-control factor for SWI/SNF complexes: in the absence of SMARCB1, DCAF5 promotes degradation of incompletely assembled (SMARCB1-deficient) SWI/SNF complexes. DCAF5 depletion allows SMARCB1-deficient SWI/SNF complexes to re-accumulate, rebind target chromatin loci, and restore SWI/SNF-mediated gene expression to levels sufficient to reverse the cancer state, including in vivo. Thus, SMARCB1-mutant cancer results not from loss of SMARCB1 function per se, but from DCAF5-mediated degradation of residual SWI/SNF complexes.\",\n      \"method\": \"Genome-wide CRISPR screen (Cancer Dependency Map); DCAF5 depletion; ChIP-seq; gene expression analysis; in vivo xenograft assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genome-wide CRISPR screen plus mechanistic ChIP-seq and in vivo validation; multiple orthogonal methods in rigorous study\",\n      \"pmids\": [\"38538798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In SMARCB1-deficient cancers, SMARCB1 loss leads to localization of H3K27ac and recruitment of CBP and p300 acetyltransferases at the KREMEN2 locus (rather than H3K27me3/EZH2 seen in SMARCB1-intact cells), resulting in KREMEN2 transcriptional upregulation. Simultaneous inhibition of CBP/p300 downregulates KREMEN2 and induces apoptosis via KREMEN1 monomerization and suppression of anti-apoptotic signaling, selectively in SMARCB1-deficient cells.\",\n      \"method\": \"Dual siRNA paralog synthetic lethal screen; ChIP-seq for H3K27me3, H3K27ac, EZH2, CBP, p300; CBP/p300 inhibitor treatment; xenograft models; KREMEN2 functional studies\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP-seq identifying mechanism plus synthetic lethality screen, in vivo validation, and functional mechanistic follow-up; multiple orthogonal methods\",\n      \"pmids\": [\"38839769\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SMARCB1 (BAF47/INI1/SNF5) is a core, essential subunit of the SWI/SNF (BAF/PBAF) ATP-dependent chromatin remodeling complexes that stabilizes complex occupancy on chromatin; its loss triggers DCAF5-mediated proteasomal degradation of residual SWI/SNF complexes, collapsing enhancer activation and opposing Polycomb repression genome-wide. Mechanistically, SMARCB1 recruits HDAC activity to the cyclin D1 promoter to repress its transcription, activates p16ink4a to engage the RB pathway for G0/G1 arrest, activates interferon-stimulated genes and represses PLK1 to control mitotic fidelity, represses IL-6 transcription by direct promoter binding, regulates actin cytoskeleton organization through suppression of Rho GTPase activity, and in renal medullary carcinoma reverses a MYC/ferroptosis-resistance transcriptional program; its Rpt1 and Rpt2 domains mediate protein multimerization, interaction with BAF155 (via Rpt1/SWIRM interface defined by crystal structure), and interaction with HIV-1 integrase (mimicking TAR RNA), while developmental stage- and cell-type-specific loss of SMARCB1 determines whether rhabdoid tumors or schwannomas arise.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SMARCB1 (BAF47/INI1/SNF5) is an essential core subunit of the SWI/SNF (BAF/PBAF) ATP-dependent chromatin-remodeling complexes that functions as a tumor suppressor by stabilizing complex occupancy on chromatin and shaping enhancer and promoter activity genome-wide [#0, #17]. It does not govern complex assembly but is required for stable BAF complex residence on chromatin; its re-expression in deficient cells increases genome-wide BAF occupancy, drives widespread enhancer activation, and opposes Polycomb-mediated repression at bivalent promoters [#17, #22]. Within the complex, SMARCB1 multimerizes through its Rpt1 and Rpt2 motifs and docks onto BAF155 via a defined Rpt1–SWIRM interface resolved by crystallography [#12, #20]. SMARCB1 loss is the initiating lesion in rhabdoid tumors and related cancers; mechanistically, loss collapses normal regulation by enabling DCAF5-mediated proteasomal degradation of residual SMARCB1-deficient SWI/SNF complexes, such that DCAF5 removal restores complex accumulation, chromatin rebinding, and reversal of the cancer state [#31]. Through these chromatin functions, SMARCB1 enforces growth arrest: it represses cyclin D1 in an HDAC-dependent manner, induces p16ink4a to activate the RB pathway and drive G0/G1 arrest, and represses mitotic genes including PLK1 while activating interferon-stimulated and senescence programs [#2, #3, #11]. SMARCB1 also acts as a direct promoter-bound repressor of IL6 and antagonizes IL6/JAK/STAT3 signaling, suppresses RhoA activity to organize the actin cytoskeleton, and in renal medullary carcinoma reverses a MYC/ferroptosis-resistance transcriptional program [#7, #24, #25, #28]. Whether SMARCB1 loss produces rhabdoid tumors or schwannomas is dictated by the developmental stage and cell lineage in which inactivation occurs [#21]. Independently of its chromatin role, SMARCB1/INI1 is incorporated into HIV-1 virions and binds HIV-1 integrase through an Rpt1-containing integrase-binding domain that structurally mimics TAR RNA, constraining integrase conformation and modulating viral late events [#10, #16, #27].\"\n  ,\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that SMARCB1's ortholog is a physical, integral component of a SWI/SNF-class chromatin-remodeling complex rather than a free-standing factor, defining its molecular context.\",\n      \"evidence\": \"Co-immunoprecipitation and biochemical fractionation of Drosophila SNR1 with BRM, plus genetic interaction with trithorax\",\n      \"pmids\": [\"7579694\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define which human SWI/SNF subunits SMARCB1 contacts directly\", \"Mechanism of recruitment to target loci unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified a recruitment logic by showing the SET domain of ALL-1/Trithorax binds INI1/SNF5, linking SWI/SNF to homeotic/leukemia-relevant target loci.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro pulldown, Co-IP, and polytene chromosome co-localization across human and Drosophila\",\n      \"pmids\": [\"9539705\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of the interaction at endogenous human loci untested\", \"Did not address remodeling vs targeting roles\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined SMARCB1 as a growth suppressor acting through the RB pathway, resolving how its loss promotes proliferation in rhabdoid tumors.\",\n      \"evidence\": \"Re-expression of INI1/hSNF5 in deficient cells with ChIP at cyclin D1, HDAC dependence, p16ink4a induction, RB hypophosphorylation, and epistatic rescue with cyclin D1, SV40 T/t, or HPV E7\",\n      \"pmids\": [\"12138206\", \"12149641\", \"12082626\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How chromatin remodeling activity connects mechanistically to cyclin D1/p16 regulation not fully resolved\", \"Rpt1/Rpt2 requirement for growth suppression mapped but not structurally explained\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed SMARCB1's ortholog is a tissue-selective, locus-directing subunit and mapped Repeat 2 as critical for protein interaction and growth control.\",\n      \"evidence\": \"Drosophila temperature-sensitive snr1E1 allele, Co-IP, in vitro binding, and genome-wide polytene localization showing partial BRM co-occupancy\",\n      \"pmids\": [\"12482982\", \"12645932\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-selectivity mechanism in mammals untested\", \"Did not define how Repeat 2 contacts the SET domain structurally\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Linked SMARCB1 to cytoskeletal regulation, expanding its role beyond cell-cycle control.\",\n      \"evidence\": \"Tetracycline-inducible INI1 re-expression with genome-wide microarray, ER-fusion direct-target mapping, and RhoA activity assay\",\n      \"pmids\": [\"15150092\", \"15454538\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular link between SMARCB1 and RhoA pathway not established\", \"Whether Rho regulation is chromatin-dependent unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed a non-chromatin function: INI1 is packaged into HIV-1 virions and is required for productive particle production and infectivity.\",\n      \"evidence\": \"HIV-1 infection of INI1-null rhabdoid lines with re-expression rescue and reverse transcriptase assays; identification of SNR1 Thr102 phosphorylation by DYRK2/MNB\",\n      \"pmids\": [\"16945155\", \"16671894\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab virology findings without independent replication\", \"Functional role of Thr102 phosphorylation in mammals untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified PLK1 repression and interferon/senescence activation as functionally relevant downstream programs of SMARCB1 controlling mitotic fidelity.\",\n      \"evidence\": \"cDNA microarray, qRT-PCR, primary tumor IHC, and RNAi knockdown of PLK1 showing mitotic arrest and apoptosis in INI1-deficient cells\",\n      \"pmids\": [\"17699849\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct promoter occupancy at PLK1 vs indirect effect not fully distinguished\", \"Interferon gene activation mechanism unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined the Rpt1/Rpt2 multimerization domain and connected multimerization to nuclear retention and HIV-1 integrase co-localization.\",\n      \"evidence\": \"Protein purification, reverse yeast two-hybrid, deletion analysis, Co-IP, in vitro strand transfer, and nuclear localization imaging\",\n      \"pmids\": [\"19398554\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of multimerization to SWI/SNF function not addressed\", \"DNA minor-groove binding role left preliminary\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated in vivo tumor-suppressor activity through Igfbp7/PI3K-AKT regulation and across multiple cancer types, extending SMARCB1 loss to causal pathogenesis.\",\n      \"evidence\": \"Retroviral re-expression with xenograft rescue, Igfbp7 re-expression, AKT inhibition in mouse tumor cells, and re-expression phenotyping in epithelioid sarcoma; HIV-1 integrase/LEDGF/DNA complex cryo-EM and stoichiometry\",\n      \"pmids\": [\"23851500\", \"23576573\", \"23593299\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SMARCB1 selects Igfbp7 vs other targets unresolved\", \"Whether Igfbp7/AKT axis operates in human rhabdoid tumors untested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established the central chromatin mechanism: SMARCB1 stabilizes BAF complex occupancy genome-wide, activating enhancers and opposing Polycomb, without affecting complex assembly.\",\n      \"evidence\": \"ChIP-seq for BAF occupancy with SMARCB1 re-expression distinguishing BAF and PBAF enhancer/promoter roles; Co-IP placing BAF47 in SWI/SNF and N-CoR-1 complexes during myogenesis\",\n      \"pmids\": [\"28945250\", \"25271443\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for chromatin stabilization vs assembly distinction not structurally defined\", \"How the same subunit partitions between activating and repressive complexes unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided structural basis for SMARCB1's interaction with the complex and dissected lineage-specific tumor outcomes.\",\n      \"evidence\": \"Crystal structure of BAF155 SWIRM–BAF47 RPT1 with ITC and NMR validation; stage- and lineage-specific conditional knockout mice generating rhabdoid tumors vs schwannomas\",\n      \"pmids\": [\"28438634\", \"28824165\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the full SMARCB1 within the assembled complex not resolved\", \"Molecular determinants linking developmental stage to tumor type unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined SMARCB1's role in development as a repressor of bivalent genes and super-enhancers required specifically for neural induction.\",\n      \"evidence\": \"SMARCB1 loss-of-function in hESCs and iPSCs with ChIP-seq, ATAC-seq, directed differentiation, and cerebral organoids showing differentiation-state-dependent effects\",\n      \"pmids\": [\"31033435\", \"32912900\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of cell-type-selective requirement unresolved\", \"How super-enhancer silencing is enforced by SMARCB1 not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified IL6/JAK/STAT3 as a SMARCB1-deficiency vulnerability and SMARCB1 as a direct IL6 promoter repressor, linking chromatin accessibility changes to a druggable signaling axis.\",\n      \"evidence\": \"ATAC-seq, ChIP at IL6 promoter, loss/gain-of-function, orthotopic xenografts and PDX with STAT3 inhibitor TTI-101; NUP210 enhancer ChIP-seq in liver cancer\",\n      \"pmids\": [\"38355560\", \"32492816\", \"33239431\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT3 activation is uniform across SMARCB1-deficient tumor types untested\", \"Context-dependent up- vs down-regulation by SMARCB1 not mechanistically unified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Solved how SMARCB1 modulates HIV-1 integrase by showing the Rpt1 domain structurally mimics TAR RNA and competes for integrase binding.\",\n      \"evidence\": \"NMR structure of INI1 Rpt1, mutational analysis, competition binding (IC50), and computational modeling of the IN-CTD interface\",\n      \"pmids\": [\"33980829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance during natural infection not established\", \"Link between integrase-binding and SWI/SNF chromatin function unexplored\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed SMARCB1 reshapes 3D enhancer architecture and reverses oncogenic transcriptional switches, including MYC enhancer looping and a MYC/ferroptosis-resistance program in renal medullary carcinoma.\",\n      \"evidence\": \"Patient-derived organoid multi-omics, chromosome conformation capture, single-cell RNA/ATAC-seq, SMARCB1 re-expression, ferroptosis assays, and hypoxia-induced SMARCB1 degradation in renal cells and a sickle cell trait mouse model\",\n      \"pmids\": [\"38040699\", \"37236926\", \"37186844\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Patient-specific enhancer heterogeneity mechanism unresolved\", \"Pathway linking hypoxia to SMARCB1 degradation not fully defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Reframed SMARCB1-mutant cancer as a consequence of DCAF5-mediated degradation of residual SWI/SNF complexes, and identified CBP/p300-driven KREMEN2 as a selective vulnerability.\",\n      \"evidence\": \"Genome-wide CRISPR screen, DCAF5 depletion, ChIP-seq, and in vivo xenografts; synthetic-lethal screen with H3K27ac/CBP/p300 ChIP-seq and CBP/p300 inhibition at the KREMEN2 locus\",\n      \"pmids\": [\"38538798\", \"38839769\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How DCAF5 recognizes incompletely assembled complexes structurally undefined\", \"Generalizability of KREMEN2 vulnerability across SMARCB1-deficient tumors untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SMARCB1 mechanistically couples its structural role in BAF complex stabilization to the diverse target-gene programs (cyclin D1, p16, PLK1, IL6, MYC) and how this is read out in a cell-type- and developmental-stage-specific manner remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model of SMARCB1 within the assembled complex on chromatin\", \"Determinants of lineage-specific target selection unknown\", \"Reconciliation of SMARCB1 as both activator and repressor at different loci incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 11, 25, 28]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [12]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 17]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [2, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [12, 19]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [0, 17]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 17, 22]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 11, 25]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [2, 3, 11]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [21, 28, 31]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [21, 22, 23]}\n    ],\n    \"complexes\": [\"SWI/SNF (BAF)\", \"PBAF\", \"N-CoR-1 repressor complex\"],\n    \"partners\": [\"SMARCC1\", \"BRM/BRG1\", \"DCAF5\", \"MyoD\", \"NUP210\", \"HIV-1 integrase\", \"LEDGF/p75\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}